CIK 0001422143 · Non-accelerated filer<br>Smaller reporting company
Kura Oncology, Inc.
Sign in to watch- Ticker
- KURA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 611547851
- Phone
- (858) 500-8800
- Business address
- 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
- Former names
- ZETA ACQUISITION CORP III
- 4 Planned sale Chief Legal Officer sold 8,805 shares at $8.94 ($78,736)
- 4 Planned sale Chief Operating Officer sold 6,892 shares at $8.94 ($61,630)
- 4 Open-market sale Chief Medical Officer sold 12,314 shares at $8.94 ($110,114)
- 4 Open-market sale President and CEO sold 36,615 shares at $8.94 ($327,419)
- 4 Open-market sale SVP, Finance & Accounting sold 4,541 shares at $8.94 ($40,607)
- 4 Open-market buy President & CEO bought 50,000 shares at $8.20 ($410,145)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market buy President and CEO bought 50,000 shares at an average $6.06 ($303,201)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Material agreement
- 8-K Event Other events
- S-8 Other Securities Offered to Employees in Benefit Plans
- 4 Derivatives Options or other derivatives
- 8-K Event Executive or director change · Shareholder vote results
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 7 of 41 · 809 filings